FDA-approved
Heart & blood
Rusfertide
Evidence
FDA approved
Class
Hepcidin mimetic peptide
KEY TAKEAWAY
Rusfertide is a synthetic peptide that mimics hepcidin, the hormone that regulates iron in the body. It is sold as Mimrylo. The FDA approved rusfertide (Mimrylo) on August 28, 2026 for adults with polycythemia vera.
Written by the Veylo editorial team · Updated
November 2026
What it is
Hepcidin mimetic peptide
Approved for
Erythrocytosis in adults with polycythemia vera
Key fact
The FDA approved rusfertide (Mimrylo) on August 28, 2026 for adults with polycythemia vera.
Route
Weekly subcutaneous injection
Evidence strength
FDA approved
Rusfertide is a synthetic peptide that mimics hepcidin, the hormone that regulates iron in the body. It is sold as Mimrylo.
It limits the iron available to make new red blood cells, which reduces overproduction of red cells.
The FDA approved rusfertide (Mimrylo) on August 28, 2026 for adults with polycythemia vera.
Erythrocytosis in adults with polycythemia vera.
Injection-site reactions and anemia were the most common adverse reactions.
U.S. FDA prescribing information for Rusfertide. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.